Navigation Links
CerSci Therapeutics Awarded $225K Phase I NIH SBIR Grant for the Treatment of Neuropathic Pain
Date:3/8/2017

DALLAS, March 8, 2017 /PRNewswire/ -- CerSci Therapeutics, a pharmaceutical development company based in Dallas, Texas, today announced it has been awarded a Phase I SBIR grant of $225,000 from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) to continue its development of novel non-opioid drug candidates for the treatment of chronic neuropathic pain. 

CerSci Therapeutics, founded in early 2015, is focused on developing next-generation non-opioid pain therapeutics for the treatment and prevention of acute and chronic pain. This grant will enable CerSci to further develop their patented and patent-pending pipeline of adenosine monophosphate activated protein kinase (AMPK) activators and peroxynitrite (PN) scavengers.  CerSci's development of non-opioid pain therapeutics addresses the critical need of finding solutions to the opioid epidemic in the U.S.  According to the U.S. Center for Disease Control, the United States is in the midst of an opioid overdose epidemic; opioids killed more than 33,000 Americans (90 people per day) in 2015, with half of all opioid overdose deaths involving a prescription opioid.

"Healthcare expenditures associated with chronic pain account for over $600 billion annually, more than the yearly cost of cancer, and heart disease combined. However, treatments available for these patients are very limited," remarked Dr. Lucas Rodriguez, Co-Founder and President of CerSci Therapeutics. "Alarmingly, 1 in 4 patients who treat chronic pain with opioids struggle with addiction. At CerSci, we believe that developing drugs, which avoid interaction with opioid receptors altogether, will aid in the relief of the opioid epidemic while providing caregivers drugs, which will truly help alleviate their patients' pain. We are incredibly energized to receive this validation from our peers at the NIH."

CerSci Therapeutics is currently fundraising to support the Investigational New Drug Application for their lead molecular asset to the Food and Drug Administration.

Media Contact:
Lucas Rodriguez
+1 (956) 279-6888
www.cersci.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cersci-therapeutics-awarded-225k-phase-i-nih-sbir-grant-for-the-treatment-of-neuropathic-pain-300419617.html


'/>"/>
SOURCE CerSci Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Dermatology Diagnostic Devices and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
2. Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
3. Bellerophon Therapeutics and Worldwide Clinical Trials Selected as Finalists in 2017 Care Awards
4. ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017
5. Mast Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
6. Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
7. How These Biotech Stocks are Faring? -- Geron, Incyte, Illumina, and Bellerophon Therapeutics
8. Nektar Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting
9. Global Breast Cancer Therapeutics Market Analysis 2016-2022: Company Profiling Covering the Financials, Recent Activities and Future Strategies - Research and Markets
10. Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Strategic Business Report 2017-2022 - Research and Markets
11. United Therapeutics Corporation To Present At Cowen And Company 37th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... As health professionals work to improve their approach to healthcare, ... doing more than filling out a survey; in many cases health professionals and patients ... health care and research on the importance of active engagement with patients and members ...
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
Breaking Medicine News(10 mins):